Reference

Preparation of pyrimidines as HIV inhibitors

Preparation of pyrimidines as HIV inhibitors. Guillemont, Jerome Emile Georges; Palandjian, Patrice; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Daeyaert, Frederik Frans Desire; Heeres, Jan; Van Aken, Koen Jeanne Alfons; Lewi, Paulus Joannes; Janssen, Paul Adriaan Jan (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2003016306 A1 27 Feb 2003, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.There are some reagents like 500287-72-9 is used in this study.Chemical with cas number 500287-72-9 also plays role. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07D403-12. ICS: C07D401-12; C07D407-12; C07D409-12; C07D413-12; C07D417-12; C07D403-14; C07D233-96; A61K031-505; C07D239-46; C07D239-48; C07C211-00. APPLICATION: WO 2002-EP8953 9 Aug 2002. PRIORITY: EP 2001-203090 13 Aug 2001; EP 2002-77748 10 Jun 2002. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1 Title compds. [I; a1:a2a3:a4, b1:b2b3:b4 = atoms to form Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl rings; n = 0-5; m = 1-4; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkyloxycarbonyl, substituted alkyl, alkylcarbonyl; R2 = OH, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, carboxyl, cyano, NO2, amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, SOpR6, NHSOpR6, COR6, NHCOH, CONHNH2, NHCOR6, C(:NH)R6, 5-membered heterocycle; X1 = NR5, NHNH, N:N, O, CO, alkanediyl, CH(OH), S, SOp, X2-alkanediyl, alkanediyl-X2; X2 = NR5, NHNH, N:N, O, CO, CH(OH), S, SOp; R3 = NHR13, NR13R14, CONHR13, CONR13R14, COR15, CH:NNHCOR16, substituted alkyl, (substituted) alkoxyalkyl, substituted alkenyl, alkynyl, alkyl substituted with OH and a second substituent, C(:NOR8)-alkyl, R7, X3R7; R4 = halo, OH, alkyl, cycloalkyl, alkoxy, cyano, nitro, polyhaloalkyl, polyhaloalkoxy, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyl, CHO, amino; R5 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxycarbonyl, etc.; R6 = alkyl, amino, polyhaloalkyl; R7 = mono-, bi-, or tricyclic (arom.) carbocyclyl, heterocyclyl; R13, R14 = alkyl, alkenyl, alkynyl optionally substituted by cyano, aminocarbonyl; R15 = cyanoalkyl, aminocarbonylalkyl; R16 = R15, R7; p = 1, 2], were prepd. Thus, 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (prepn. given) and 4-(2-cyanoethenyl)-2,6-dimethylaniline were stirred together at 150° for 1 h to give 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amin o]benzonitrile. The latter inhibited HIV-induced cytopathic effect in MT-4 cells with pIC50 = 9.4. ..

Preparation of pyrimidines as HIV inhibitors

Preparation of pyrimidines as HIV inhibitors. Guillemont, Jerome Emile Georges; Palandjian, Patrice; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Daeyaert, Frederik Frans Desire; Heeres, Jan; Van Aken, Koen Jeanne Alfons; Lewi, Paulus Joannes; Janssen, Paul Adriaan Jan (Janssen Pharmaceutica N.V., Belg.). PCT Int. Appl. WO 2003016306 A1 27 Feb 2003, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.There are some reagents like 500287-72-9 is used in this study.Chemical with cas number 500287-72-9 also plays role. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07D403-12. ICS: C07D401-12; C07D407-12; C07D409-12; C07D413-12; C07D417-12; C07D403-14; C07D233-96; A61K031-505; C07D239-46; C07D239-48; C07C211-00. APPLICATION: WO 2002-EP8953 9 Aug 2002. PRIORITY: EP 2001-203090 13 Aug 2001; EP 2002-77748 10 Jun 2002. DOCUMENT TYPE: Patent CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1 Title compds. [I; a1:a2a3:a4, b1:b2b3:b4 = atoms to form Ph, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl rings; n = 0-5; m = 1-4; R1 = H, aryl, CHO, alkylcarbonyl, alkyl, alkyloxycarbonyl, substituted alkyl, alkylcarbonyl; R2 = OH, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, carboxyl, cyano, NO2, amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, SOpR6, NHSOpR6, COR6, NHCOH, CONHNH2, NHCOR6, C(:NH)R6, 5-membered heterocycle; X1 = NR5, NHNH, N:N, O, CO, alkanediyl, CH(OH), S, SOp, X2-alkanediyl, alkanediyl-X2; X2 = NR5, NHNH, N:N, O, CO, CH(OH), S, SOp; R3 = NHR13, NR13R14, CONHR13, CONR13R14, COR15, CH:NNHCOR16, substituted alkyl, (substituted) alkoxyalkyl, substituted alkenyl, alkynyl, alkyl substituted with OH and a second substituent, C(:NOR8)-alkyl, R7, X3R7; R4 = halo, OH, alkyl, cycloalkyl, alkoxy, cyano, nitro, polyhaloalkyl, polyhaloalkoxy, aminocarbonyl, alkyloxycarbonyl, alkylcarbonyl, CHO, amino; R5 = H, aryl, CHO, alkylcarbonyl, alkyl, alkoxycarbonyl, etc.; R6 = alkyl, amino, polyhaloalkyl; R7 = mono-, bi-, or tricyclic (arom.) carbocyclyl, heterocyclyl; R13, R14 = alkyl, alkenyl, alkynyl optionally substituted by cyano, aminocarbonyl; R15 = cyanoalkyl, aminocarbonylalkyl; R16 = R15, R7; p = 1, 2], were prepd. Thus, 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (prepn. given) and 4-(2-cyanoethenyl)-2,6-dimethylaniline were stirred together at 150° for 1 h to give 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amin o]benzonitrile. The latter inhibited HIV-induced cytopathic effect in MT-4 cells with pIC50 = 9.4. ..